Population Estimate of People with Clinical AD and Mild Cognitive Impairment in the United States (2020–2060)
By Kumar B. Rajan, J. Weuve, Lisa L. Barnes, Elizabeth A Mcaninch, Robert S. Wilson, Denis A. Evans. Alzheimer's & Dementia, 2021
1,026 citations recorded by the source corpus.
The estimate of people with clinical Alzheimer's disease (AD) and mild cognitive impairment provides an understanding of the disease burden.
Subfields: Conservation, History, Political Science and International Relations
View Paper: https://www.semanticscholar.org/paper/b602087626c2aa8fd21c0974efb0c3ed16c46c2c
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
Citations in the corpus
- Nanomedicine-Driven Modulation of the Gut–Brain Axis: Innovative Approaches to Managing Chronic Inflammation in Alzheimer’s and Parkinson’s Disease (2025, unknown): “Once calibrated and validated, these models enable testing different intervention scenarios to evaluate their impacts on the projected AD/ADRD burden, which is expected to grow from 7 million to 13 million individuals by 2050 [287].”
- Memory Deficits in Parkinson’s Disease Are Associated with Impaired Attentional Filtering and Memory Consolidation Processes (2023, background): “Episodic memory problems have been reported as the earliest neurobehavioral deficits in Alzheimer’s disease (AD) [36], the most common age-related neurodegenerative disorder, comprising about 50–70% of dementia cases [37].”